The analysis of biological data has suffered for decades from fragmentation, where each modality — genetics, imaging, DNA — is treated in isolation. The Parisian startup Bioptimus wants to solve this problem by introducing generative AI models capable of integrating and linking these different scales of data.
A multi-scale and multi-modal approach
Bioptimus AI models leverage multi-scale data ranging from microscopic genetic mutations to organic tissue analysis. The objective is to create connections between these different dimensions to offer a global vision of organizations.
In 2025, Bioptimus will launch a model capable of linking genetic data to biological images, a first commercial product dedicated to applications such as the detection of mutations causing cancer.
A strategy based on exclusive data
To guarantee the performance of its models, Bioptimus combines public and private data. The startup has established strategic partnerships with research laboratories and benefits from access to patient data from Owkin, which incubated the company. This strategy differentiates Bioptimus from other AI players, often dependent on common data sources.
Growing competition in biotechnology
Bioptimus operates in a highly competitive sector, with players like Google (via DeepMind/AlphaFold) and Microsoft investing heavily in applications of AI to life sciences. Financing needs will be increasingly important for startups operating in this area.
Fundraising to accelerate development
Bioptimus therefore announces having raised €41 million during a Series A funding round led by Cathay Innovation, with the participation of Bpifrance, Sofinnova Partners, Andera Partners and Hitachi Ventures. International investors such as Sunrise, Boom Capital Ventures and Pomifer Capital also contributed. This funding is in addition to the €35 million raised in Seed and will support the development of the startup’s first commercial model, while supporting the recruitment of commercial and technical profiles.
Founded by Jean-Philippe Vert, David Cahané and Eric Durand, Bioptimus aims to change the understanding of living organisms and biological processes.
The latest articles by THE EDITORIAL OF FRENCHWEB.FR (see all)
Tech
